Condition or disease | Intervention/treatment |
---|---|
Lung Neoplasms Lung Cancer Neoplasm of Lung Non Small Cell Lung Cancer | Other: Circulating tumour DNA (ctDNA) |
Study Type : | Observational |
Actual Enrollment : | 40 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility |
Actual Study Start Date : | May 1, 2019 |
Actual Primary Completion Date : | December 31, 2020 |
Actual Study Completion Date : | December 31, 2020 |
Group/Cohort | Intervention/treatment |
---|---|
Cohort 1
|
Other: Circulating tumour DNA (ctDNA)
Circulating tumour DNA (ctDNA) will be isolated from blood samples
|
Cohort 2
|
Other: Circulating tumour DNA (ctDNA)
Circulating tumour DNA (ctDNA) will be isolated from blood samples
|
Cohort 3
|
Other: Circulating tumour DNA (ctDNA)
Circulating tumour DNA (ctDNA) will be isolated from blood samples
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Cohort 1
Cohort 2
Cohort 3
Exclusion Criteria:
Canada, Ontario | |
London Regional Cancer Program | |
London, Ontario, Canada, N6A 5W9 |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | April 30, 2019 | ||||
First Posted Date | June 14, 2019 | ||||
Last Update Posted Date | February 18, 2021 | ||||
Actual Study Start Date | May 1, 2019 | ||||
Actual Primary Completion Date | December 31, 2020 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
|
||||
Original Primary Outcome Measures |
|
||||
Change History | |||||
Current Secondary Outcome Measures |
|
||||
Original Secondary Outcome Measures |
|
||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility | ||||
Official Title | CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility | ||||
Brief Summary | This is a prospective observation study in patients with non-small cell lung cancer (NSCLC) starting either cytotoxic chemotherapy or radiation therapy. It will assess changes in circulating tumor DNA (ctDNA) in the days following the initiation of treatment, as well as longitudinal monitoring, to assess the dynamics and value of ctDNA in stage III-IV NSCLC. | ||||
Detailed Description | The study consists of three cohorts of patients initiating a new treatment for their NSCLC. The cohorts of (1) patients starting concurrent chemotherapy and radiation for stage III NSCLC (2) patients with advanced NSCLC starting cytotoxic chemotherapy (with or without pembrolizumab) (3) patients with advanced NSCLC starting palliative radiation therapy. This study aims to study the changes in ctDNA levels following a new treatment in lung cancer patients and to explore if the diagnostic utility of ctDNA testing is improved immediately following treatment when tumour cells are actively dying. It will also examine the changes in ctDNA levels and mutational analysis longitudinally. | ||||
Study Type | Observational | ||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Retention: Samples With DNA Description:
Circulating tumour DNA (ctDNA) will be isolated from blood samples and stored for potential future testing.
|
||||
Sampling Method | Non-Probability Sample | ||||
Study Population | Patients receiving treatment at the London Regional Cancer Program in London, Ontario, Canada. | ||||
Condition |
|
||||
Intervention | Other: Circulating tumour DNA (ctDNA)
Circulating tumour DNA (ctDNA) will be isolated from blood samples
|
||||
Study Groups/Cohorts |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Completed | ||||
Actual Enrollment |
40 | ||||
Original Estimated Enrollment |
30 | ||||
Actual Study Completion Date | December 31, 2020 | ||||
Actual Primary Completion Date | December 31, 2020 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria |
Inclusion Criteria:
Cohort 1
Cohort 2
Cohort 3
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | No | ||||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries | Canada | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT03986463 | ||||
Other Study ID Numbers | CITaDeL | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement |
|
||||
Responsible Party | Lawson Health Research Institute | ||||
Study Sponsor | Lawson Health Research Institute | ||||
Collaborators | Not Provided | ||||
Investigators | Not Provided | ||||
PRS Account | Lawson Health Research Institute | ||||
Verification Date | August 2020 |